Tandlægeselskabet Colosseum Holbæk ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  0.5% 0.5% 0.5% 0.5% 0.5%  
Bankruptcy risk  4.2% 6.3% 3.0% 7.3% 7.1%  
Credit score (0-100)  50 37 56 32 33  
Credit rating  BBB BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  1,406 6,677 7,508 7,429 8,599  
EBITDA  240 180 849 810 1,070  
EBIT  141 -236 451 -74.4 171  
Pre-tax profit (PTP)  117.4 -336.5 357.7 -132.9 151.1  
Net earnings  91.5 -310.7 357.7 -132.9 115.1  
Pre-tax profit without non-rec. items  117 -337 358 -133 151  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  2,212 2,021 3,496 2,765 4,431  
Shareholders equity total  132 -179 179 45.6 161  
Interest-bearing liabilities  2,414 2,009 2,163 0.0 0.0  
Balance sheet total (assets)  3,670 4,217 4,831 3,821 5,218  

Net Debt  1,844 549 1,704 -418 -114  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  1,406 6,677 7,508 7,429 8,599  
Gross profit growth  0.0% 374.9% 12.5% -1.0% 15.8%  
Employees  10 12 12 11 12  
Employee growth %  0.0% 20.0% 0.0% -8.3% 9.1%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  3,670 4,217 4,831 3,821 5,218  
Balance sheet change%  0.0% 14.9% 14.6% -20.9% 36.6%  
Added value  240.3 180.1 848.8 323.3 1,070.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  2,113 -607 1,077 -1,616 767  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 -1.0 1.0 -1.0 1.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  10.1% -3.5% 6.0% -1.0% 2.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  3.9% -5.8% 9.8% -1.7% 4.0%  
ROI %  5.4% -9.6% 18.6% -5.6% 173.3%  
ROE %  69.6% -14.3% 16.3% -118.6% 111.6%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  3.6% -4.2% 3.7% 1.2% 3.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  767.3% 304.7% 200.8% -51.6% -10.6%  
Gearing %  1,835.2% -1,121.2% 1,211.5% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  2.1% 4.6% 4.5% 5.4% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.9 0.8 0.3 0.3 0.1  
Current Ratio  0.9 0.8 0.4 0.3 0.2  
Cash and cash equivalent  569.9 1,460.4 458.9 418.3 113.6  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -181.6 -658.3 -2,420.6 -2,473.3 -4,179.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  24 15 71 29 89  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  24 15 71 74 89  
EBIT / employee  14 -20 38 -7 14  
Net earnings / employee  9 -26 30 -12 10